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The tumor suppressor protein p53 plays an important role in
maternal reproduction in mice through transcriptional regulation
of leukemia inhibitory factor (LIF), a cytokine crucial for blastocyst
implantation. To determine whether these observations could be
extended to humans, a list of single-nucleotide polymorphisms
(SNPs) in the p53 pathway that can modify the function of p53 was
assembled and used to study their impact on human fertility. The
p53 allele encoding proline at codon 72 (P72) was found to be
significantly enriched over the allele encoding arginine (R72)
among in vitro fertilization (IVF) patients. The P72 allele serves as
a risk factor for implantation failure. LIF levels are significantly
lower in cells with the P72 allele than in cells with the R72 allele,
which may contribute to the decreased implantation and fertility
associatedwith the P72 allele. Selected alleles in SNPs in LIF,Mdm2,
Mdm4, and Hausp genes, each of which regulates p53 levels in
cells, are also enriched in IVF patients. Interestingly, the role of
these SNPs on fertility was much reduced or absent in patients
older than 35 years of age, indicating that other functionsmay play
amore important role in infertility in olderwomen. The association
of SNPs in the p53 pathway with human fertility suggests that p53
regulates the efficiency of human reproduction. These results also
provide a plausible explanation for the evolutionary positive
selection of some alleles in the p53 pathway and demonstrate the
alleles in the p53 pathway as a good example of antagonistic
pleiotropy.
LIF  implantation  selection  alleles
The tumor suppressor protein p53 plays a pivotal role incoordinating cellular responses to genotoxic stressors and in
maintaining genomic stability (1). In response to stress, p53
activation leads to various cellular responses, including apopto-
sis, cell cycle arrest, or senescence. The p53 pathway is crucial for
tumor prevention. In some circumstances, disruption of normal
p53 function is a prerequisite for the development or progression
of tumors. p53 is the most frequently mutated gene in human
tumors; over 50% of tumors harbor mutations in the p53 gene (2).
Recently, a previously undescribed function of p53 in repro-
duction has been uncovered; p53 plays an important role in
blastocyst implantation and maternal reproduction through reg-
ulation of leukemia inhibitory factor (LIF) inmice (3). LIF is one
of the most important cytokines in implantation. In many
mammalian species, including mouse and human, transiently
increased expression of uterine LIF is coincident with the onset
of implantation. LIF/ mice have a defect in maternal repro-
duction attributable to the failure of implantation (4). p53/
mice have impaired implantation because of decreased uterine
LIF levels. Injection of exogenous LIF into p53/ female mice
can significantly enhance implantation and rescue impaired
reproduction (3).
A significant proportion of human infertility remains unex-
plained, and inefficient implantation is thought to be an impor-
tant cause of infertility (5). As in mice, LIF has been suggested
to be an important factor for implantation in humans. LIF levels
in the majority of women with unexplained infertility are sig-
nificantly decreased, as measured in uterine flushing (6). The
regulation of LIF and blastocyst implantation by p53 in mice
suggests a potential role of p53 and its pathway in human fertility.
In humans, single-nucleotide polymorphisms (SNPs) have
been identified in genes at critical nodes in the p53 pathways,
including p53, Mdm2, Mdm4, and Hausp. Some SNPs, such as
p53 codon 72 SNP and SNP309 of Mdm2, have been shown to
modify the activity or the levels of the p53 protein and influence
cancer susceptibility (7–9). Furthermore, recent studies of the
haplotype structures of these SNPs in the p53,Mdm2, andMdm4
genes in populations with different ethnic backgrounds suggest
that these genes are under evolutionary selective pressures for
certain alleles (10, 11). It is therefore possible that the genes
undergoing selection in the p53 pathway might influence human
fertility. p53 codon 72 SNP is a common coding polymorphism
(12) which results in either an arginine (R72) or proline (P72)
residue at codon 72. The p53 P72 allele is weaker than the R72
allele in inducing apoptosis and suppressing cellular transfor-
mation but appears to be better at initiating senescence and cell
cycle arrest (7, 13). Notably, Coulam and colleagues (5) have
demonstrated that P72 is enriched in patients from an in vitro
fertilization (IVF) clinic with recurrent implantation failure.
Mdm2 SNP309 (a T-to-G change in Mdm2 intronic promoter
region) increases Mdm2 expression levels and leads to attenu-
ation of p53 function (9). Recent studies on the haplotype SNP
structures of Mdm4 and Hausp, 2 critical regulators of p53,
indicate the presence of candidate SNPs that influence p53
function and subsequent cancer risk (11). Both genes have an
allele that appears to be under positive evolutionary selection.
Mdm4 is a structural homolog of Mdm2 and is a major inhibitor
of p53 activity. HAUSP (herpesvirus-associated ubiquitin-
specific protease) can stabilize Mdm2, Mdm4, and p53 as a
specific deubiquitinase and is an important regulator of the p53
pathway (14).
To study the potential role of the p53 pathway in human
fertility, these SNPs in the p53 pathway were assessed in a cohort
of women with fertility problems in an IVF clinic along with a
control group.We found that p53 codon 72 SNP had a significant
impact on LIF expression levels, which could, in turn, result in
different implantation rates and lead to different pregnancy
outcomes in human populations. Indeed, we found that P72 was
enriched in IVF patients and served as a risk factor for implan-
tation failure and decreased pregnancy rates after IVF, espe-
cially in patients younger than 35 years of age. Selected alleles of
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SNPs in LIF,Mdm2,Mdm4, andHausp genes were also enriched
in IVF patients. The observation that these at-risk alleles of
SNPs in the p53 pathway act predominantly on patients younger
than 35 years of age suggests that the LIF levels play a major role
in implantation failure in this group. In women older than the
age of 35 years, other factors, such as aneuploidy, may predom-
inate, because the statistical role of p53 and LIF becomes less
noticeable in the cohort. These results clearly demonstrate the
association of SNPs in the p53 pathway with human fertility and
strongly suggest that p53 regulates human reproduction.
Results
The p53 Codon 72 SNP Has Differential Transcriptional Induction of LIF.
It is well established that p53 codon 72 SNP has different
transcriptional activity toward a subset of p53 target genes (7).
To examine the impact of p53 codon 72 SNP on induction of LIF,
human Saos2 (p53-null osteosarcoma) cells stably transfected
with temperature-sensitive p53 P72 and R72 alleles (7), which
express mutant p53 at 39 °C andWT p53 at 32 °C, were used. We
analyzed the expression levels of several p53 target genes in this
pair of isogenic cell lines following culture at 32 °C for 8 and 16 h
by real-time PCR. As shown in Table 1, the R72 allele prefer-
entially induces higher levels of transcription than the P72 allele
for some p53 target genes, such as Puma and Gadd45, but these
alleles show comparable transactivation (TA) of p21, cyclin G1,
and Apaf-1. Notably, the regulation of LIF is significantly
different in these cells; the LIF expression levels are about 2-fold
higher in cells containing active p53 R72 protein compared with
P72 protein. The regulation of LIF transcription by p53 codon 72
SNP was further analyzed in a pair of human melanoma cell lines
containing WT p53 R72 (WM115) and P72 (WM278), using
gamma-irradiation (IR) as a stress signal to activate endogenous
p53. Cells were irradiated (5 Gy), and the expression levels of
LIF were measured at 16 h after IR. As shown in Fig. 1, the
induction of LIF was over 2-fold higher in cells with the R72
allele than in cells with the P72 allele. Because LIF is an
important factor for implantation, the regulation of LIF expres-
sion by p53 codon 72 SNP suggests that the codon 72 SNP of p53
may affect implantation rate and fertility in humans.
The p53 P72 Allele Is Enriched in Young Patients with Infertility. To
investigate the impact of p53 codon 72 SNP on human fertility,
the frequency of these polymorphic variants was assessed in an
IVF patient population recruited at Weill Cornell Medical
College. A total of 272 women with unexplained infertility were
included in this study. Of these, 166 patients are younger than 35
years of age and 106 patients are older than 35 years of age.
Maternal age has a significant negative impact on fertility, and
a major underlying cause seems to be chromosomal aneuploidy.
To exclude the contribution of aneuploidy on infertility and to
decrease pregnancy failure after IVF, patients older than 35
years of age included in this study underwent donor IVF
procedures using oocytes from a donor of a younger age (15).
Patients younger than 35 years of age underwent fresh IVF
procedures using their own oocytes. Lymphoblastoid cell lines
established from 100 healthy Caucasian individuals (Caucasian
100) and women recruited as controls for the Women’s Insights
and Shared Experiences (WISE) study were used as controls to
determine the frequency of SNPs in a normal population. As
shown in Table 2, the frequency of P72, which is weaker in the
induction of LIF expression, is significantly enriched in the IVF
patient group (33.1% vs. 22.7%; P  1.8E-06). The enrichment
is more significant in young patients (35 years), who are more
likely to have implantation problems compared with older
patients, who also demonstrate enhanced aneuploidy. The same
trend is observed in older patients (35 years), but it is less
significant (P  0.03). These results confirm those of Coulam
and colleagues (5) and strongly indicate that P72 is involved in
human fertility, especially at the implantation stage, which is
consistent with our previous finding that p53 regulates implan-
tation in mice.
The p53 P72 Allele Is Associated with Poor Implantation and Preg-
nancy Rates in Young Patients with Unexplained Infertility. The
impact of p53 codon 72 SNP on implantation and pregnancy
after IVF was investigated in patients with infertility. Implan-
tation rate was calculated as gestational sacs per embryo trans-
ferred. A serum human chorionic gonadotropin (hCG) level 5
mIU/mL at 9–11 days after embryo transfer was defined as the
establishment of pregnancy. Evidence of fetal cardiac activity by
transvaginal ultrasound examination at 6–7 weeks of gestational
age was defined as a clinical pregnancy.
In young patients under the age of 35 years, P72 appears to be
Table 1. Induction of p53 target genes in cells containing SNPs at p53 gene codon 72
8 h after p53 activation 16 h after p53 activation
Proline Arginine Proline Arginine
LIF 2.14  0.26 4.24  0.37 3.17  0.35 6.94  0.71
Puma 8.22  1.51 17.22  1.92 10.76  0.95 18.19  1.97
Gadd45 10.05  1.63 18.1  1.72 11.84  1.02 18.51  1.67
Fas 4.94  0.38 6.5  0.57 4.99  0.43 6.11  0.54
Cyclin G1 3.22  0.45 3.8  0.28 5.37  0.61 5.87  0.45
Apaf-1 2.92  0.39 2.71  0.32 2.33  0.19 2.66  0.22
p21 6.84  1.51 5.75  0.42 10.07  0.89 9.86  0.92
Soas-2 cells containingp53P72andR72expressionplasmidswere culturedat 32°C for 8hand16h toexpression
of active p53 protein. The expression levels of a panel of p53 target genes were determined by Taqman real-time
PCR and normalized to the levels of -actin. The induction fold of these genes was calculated at each time point.
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Fig. 1. The regulation of LIF expression levels by p53 with different SNPs at
codon72.Humanmelanoma cell lines homozygous for R72 (WM115, gray bar)
and homozygous for P72 (WM278, black bar) were irradiated with 5 Gy of
gamma-IR. The RNA expression levels of LIF were measured at 16 h after IR by
real-time PCR. All values were normalized to the levels of -actin, and the
averages of 3 independent experiments are represented. con, control.
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a risk factor for implantation failure. The implantation rate is
significantly lower in patients homozygous for P72 (19%) com-
pared with patients carrying at least 1 allele of R72 (42%) (P 
0.0028), which, in turn, leads to a significantly lower clinical
pregnancy rate in these patients homozygous for P72 (Fig. 2). In
contrast, in older patients in whom chromosomal aneuploidy
appears to be a major contributing factor to infertility, there is
no significant difference on implantation and pregnancy rates
among patients carrying different genotypes at p53 codon 72.
The strong association of P72 with decreased fertility and
implantation in young patients suggests that p53 regulates hu-
man fertility. This p53 polymorphism at codon 72 may account
for an increased risk for infertility for a subset of young women
because of lower LIF levels leading to impaired implantation.
A SNP in LIF Is Enriched in Young Patients with Infertility. The human
LIF gene, which plays an essential role in implantation, has been
recently identified as a p53 target gene (3). p53 regulates both
basal and inducible transcription of LIF through direct sequence
specific DNA binding and transcriptional activation. The impor-
tance of LIF variants in human fertility was investigated, and an
association of a SNP in the 3UTR of the LIF (rs929271) gene
with human fertility was observed in this study. The G allele of
this SNP is found at a rate of30% in Caucasian Americans and
does not exist in African Americans, which suggests that this SNP
arose later in evolution after the migration out of Africa. As
shown in Table 2, the G allele is significantly enriched in young
patients under the age of 35 years (36.7% vs. 28.6%; P  0.008)
but not in older patients (31.1% vs. 28.6%; P  0.43). Further-
more, in the control population of the WISE study, there is an
association of the G allele with a history of fertility medication
use [odds ratio (OR)  2.5, 95% confidence interval (CI):
1.13–5.55] (Table 3), indicating the association of the G allele
with infertility. These results demonstrate an association of a
SNP in the LIF gene with infertility, especially in patients under
the age of 35 years.
Table 2. Significant enrichment of selected alleles of genes in the p53 pathway in IVF patients
Gene
Genotype
of SNP
Controls IVF patients
Caucasian
100 n (%)
WISE control
n (%)
Total
n (%)
35 years  35 years Total
n (%) P* n (%) P* n (%) P*
p53 (rs1042522) GG 57 (56.4) 653 (61.0) 710 (60.6) 68 (41.0) 2.8E-05† 53 (50.0) 0.13 121 (44.5) 2.1E-05†
GC 35 (34.7) 357 (33.3) 392 (33.4) 79 (47.6) 43 (40.6) 122 (44.8)
CC 9 (8.9) 61 (5.7) 70 (6.0) 19 (11.4) 10 (9.4) 29 (10.7)
G 149 (73.8) 1663 (77.6) 1812 (77.3) 215 (64.8) 1.8E-06† 149 (70.3) 0.03† 364 (66.9) 1.8E-06†
C 53 (26.2) 479 (22.4) 532 (22.7) 117 (35.2) 63 (29.7) 180 (33.1)
LIF (rs929271) TT 49 (49.5) 357 (54.2) 406 (53.6) 65 (39.1) 0.01† 50 (47.2) 0.48 115 (42.3) 0.02†
GT 37 (37.4) 233 (35.4) 270 (35.6) 80 (48.2) 46 (43.4) 126 (46.3)
GG 13 (13.1) 69 (10.5) 82 (10.8) 21 (12.7) 10 (9.4) 31 (11.4)
T 135 (68.2) 947 (71.8) 1082 (71.4) 210 (63.3) 0.008† 146 (68.9) 0.43 356 (65.4) 0.02†
G 63 (31.8) 371 (28.2) 434 (28.6) 122 (36.7) 66 (31.1) 188 (34.6)
Mdm2 (rs2279744) TT 42 (42.0) 492 (40.7) 534 (40.8) 48 (28.9) 0.05† 37 (34.9) 0.70 85 (31.2) 0.05a
TG 45 (45.0) 526 (43.5) 571 (43.7) 88 (53.0) 49 (46.2) 138 (50.7)
GG 13 (13.0) 190 (15.7) 203 (15.5) 30 (18.1) 20 (18.9) 49 (18.0)
T 129 (64.5) 1510 (62.5) 1639 (62.7) 184 (55.7) 0.03† 123 (58.0) 0.35 308 (56.6) 0.03†
G 71 (35.5) 906 (37.5) 977 (37.3) 148 (44.3) 89 (42.0) 236 (43.4)
Mdm4 (rs1563828) CC 46 (45.5) 560 (48.2) 606 (48.0) 62 (37.3) 0.07 42 (39.6) 0.01† 104 (38.2) 0.01†
TC 47 (46.5) 468 (40.3) 515 (40.8) 81 (48.8) 41 (38.7) 122 (44.9)
TT 8 (8.0) 134 (11.5) 142 (11.2) 23 (13.8) 23 (21.7) 46 (16.9)
C 139 (68.8) 1588 (68.3) 1727 (68.4) 205 (61.7) 0.05† 125 (59.0) 0.02† 330 (60.7) 0.002†
T 63 (31.2) 736 (31.7) 799 (31.6) 127 (38.3) 87 (41.0) 214 (39.3)
Hausp (rs1529916) GG 45 (45.0) NA 45 (45.0) 61 (36.7) 0.003† 51 (40.2) 0.05† 112 (41.2) 0.006†
GA 47 (47.0) NA 47 (47.0) 64 (38.6) 36 (38.2) 100 (36.8)
AA 8 (8.0) NA 8 (8.0) 41 (24.7) 19 (17.9) 60 (22.1)
G 137 (68.5) NA 137 (68.5) 186 (56.0) 0.004† 138 (65.1) 0.46 324 (59.6) 0.03†
A 63 (31.5) NA 63 (31.5) 146 (44.0) 74 (34.9) 220 (40.4)
*2 test.
†Significant difference observed between IVF patients and controls.
NA, not analyzed.
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Fig. 2. Implantation rate andpregnancy rate after IVF in youngpatientswith
infertility carryingdifferentgenotypes atp53 codon72. Implantation ratewas
calculated as gestations sacs/embryo transferred. A serum hCG level 5
mIU/mL at 9–11 days after embryo transfer was defined as a successful
pregnancy. Clinical pregnancy rate is defined as fetal cardiac activity detected
by transvaginal ultrasound at 6–7 weeks of gestation. p53 P72 was associated
with a significantly lower implantation rate (A), pregnancy rate (B), and
clinical pregnancy rate (C). Arg, arginine; Pro, proline.
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SNPs of Genes in the p53 Pathway Are Associated with Infertility. To
investigate the impact of the p53 pathway on human fertility
further, SNPs in key regulators of the p53 pathway were geno-
typed in the IVF patient population. The SNPs examined include
SNP309 in Mdm2, a SNP in the Mdm4 gene (rs2279744), and a
SNP in the Hausp gene (rs1529916). All these SNPs appear to
be under evolutionary selection pressures in the Caucasian
population. For Mdm2 SNP309, the frequency of the G allele is
43% in Caucasian Americans and only 10% in African Amer-
icans. The study of the haplotype structures of the Mdm2 genes
from African Americans, Caucasians, and Asians demonstrates
that there are many different haplotypes for the T allele (it is
older and has undergone mutations and recombinations many
times), although there is only 1G-allele haplotype found in Asian
and Caucasian populations (arose more recently) (10). Similarly,
the Mdm4 gene and the Hausp gene appear to have haplotypes
in Caucasians under positive selection. In the Hausp gene, the
frequency of the A allele is 33% in Caucasian Americans and
only 16% in African Americans. Interestingly, there are many
different haplotypes for the G allele, whereas there is only 1
A-allele haplotype found in Caucasian populations (arose more
recently) (Fig. 3). For the Mdm4 gene, the frequency of the C
allele is 67% in Caucasian Americans and only 30% in African
Americans. There is a dominant C-allele haplotype in the
Caucasian population and many different haplotypes for the T
allele. These results suggest that the T allele is ancestral to the
G allele in theMdm2 gene, theG allele is ancestral to the A allele
in the Hausp gene, and the T allele is ancestral to the C allele
in the Mdm4 gene. Considering the recent establishment of the
G-allele haplotype of Mdm2, the A-allele haplotype of Hausp,
and the C-allele haplotype of Mdm4 in the Caucasian and Asian
populations, along with their relatively high frequency in these
populations, these observations suggest that these haplotypes are
under positive selection in Caucasian and Asian populations and
indicate the presence of candidate functional SNPs in these
haplotypes that influence p53 function. These conclusions have
been quantitatively verified using several approaches to deter-
mine the selection of genes in these populations (10, 11).
The evolutionary positive selection of these alleles in key
nodes of the p53 pathwaymay have come about as a consequence
of the need to keep the activity of the genes that regulate the p53
pathway at balanced and appropriate levels. The impact of p53
on reproduction is much more likely to be the most important
selection pressure, because the impact of p53 in cancer risk and
longevity occurs mainly in postreproductive years. To test this
premise, we analyzed the frequency of SNPs of other genes in the
p53 pathway in IVF patients. As shown in Table 2, there is clear
Table 3. Adjusted ORs with 95% CIs for the effect of LIF
genotype on reproductive characteristic in 679 WISE women
Genotype of SNP
(rs929271)
Any use of fertility
medications
T (1)
G 2.50 (1.13–5.55)
SNP ID
dbSNP ID (rs) 
chromosome position
ancestral/recent allele
exonintron
1
899253
8895636
C/A
2
1529916
8898691
G/A
3
2289109
8900329
G/T
4
2304466
8903428
G/A
5
1347580
8907049
C/T
6
2447914
8913141
A/G
7
12708738
8920187
G/A
8
9940652
8922759
T/C
10
1542541
8933901
A/G
11
1471435
8942625
T/C
9
2447911
8926166
T/G
12
1471435
8942625
C/A
Chromosome 16
G A
CGG
AAG
CGGGC AAGGT
0.15 0.32
0.330.67
0.15
0.32
AAGGTGGCGGGCAA
0.10
0.07
Hausp haplotype frequencies (caucasian )
C G  T
0.46
AGT
0.07
CGTAC
0.46
AGTAC
0.07
AAGGTGGTGATCCGGGCAACTGTA
0.07
ANCESTRAL
HAPLOTYPE
CGGGCAG CGTACAA CGTACGA AGTACAA
0.060.020.440.05 0.32
CGGGCAGTTATC
0.05
CGTACAACTGTA
CGTACAACTACC
0.30
AGTACAACTATC
0.05
0.31
CGTACAACTATC
0.06
G A
CGG
AAG
CGGGC AAGGT
0.43
0.16
0.160.84
0.34 0.12
SNPs  1  ,2,   3
SNP 2
AAGGTGG
CGGGCAA
0.19
0.16
Hausp  haplotype frequencies ( african-american )
CGT
0.36
CGGGT
0.08
SNPs   …   4,5
AGT
0.04
CGTAC
0.18
AGTAC
0.04
… 6,7
AAGGTGGTGATC
CGGGCAACTGTA
… 8,9,10,11,12
CGGGCAGTTGTC
0.04
0.08
0.05
CGTGC
0.17
AAGAT
0.04
CGGGCAG
CGGGCGG
CGGGTGG CGTACAA
CGTACGA
AGTACAA  
0.04
CGTGCAA AAGATGG
0.170.05
0.120.05
0.05
0.08
0.12 0.04
CGGGCAGTTATC
0.02
CGGGCGGTTATC
0.04
CGGGTGGTGATC
CGTACAACTGTA
CGTACAACTACC
0.03
CGTGCAACTGTA
0.13
CGTGCAACTGTC
0.03
AGTACAACTATC
0.02
0.09
AAGATGGTGATC
0.04
A
B C
Fig. 3. Haplotype structure of the Hausp gene in African-American and Caucasian populations. (A) Schematic diagram of the Hausp gene and the SNPs
genotyped for the study of haplotype structure. (B and C) Inferred haplotype frequencies in African-American and Caucasian populations, respectively. dbSNP,
data base-SNP; ID, identification; rs, reference sequence.
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enrichment of selected SNPs in IVF patients. The significant
enrichment of the Mdm2 SNP309 G allele and the A allele of
Hausp gene was observed in young patients but not in older
patients; this finding is similar to the observation made with the
SNP in the LIF gene and p53 codon 72. These results demon-
strate an association of the Mdm2 SNP309 G allele and Hausp
A allele with infertility, especially in patients more likely to have
implantation problems (under the age of 35 years), suggesting
that these SNPs in Mdm2 and Hausp may have an impact on
human fertility through attenuation of the p53 pathway. Inter-
estingly, the enrichment of the Mdm4 T allele behaves as a
significant variable in both the older patient group (41.0% vs.
31%; P  0.02) and in young patients under the age of 35 years
(38.3% vs. 31%; P  0.05). This result suggests that Mdm4 may
regulate fertility through p53-dependent and p53-independent
pathways.
Discussion
The tumor suppressor p53 plays a crucial role in maintaining
genomic stability and tumor prevention in somatic cells (1).
Mdm2, Mdm4, and Hausp are all critical regulators of the p53
protein. Mdm2 binds to the p53 protein and degrades p53
through polyubiquitination of the p53 protein, sending it to the
proteosome and blocking its ability to function as a transcription
factor. Mdm4, a structural homolog of Mdm2, also binds to the
amino terminus of p53 and is a key inhibitor of this protein.
HAUSP is a critical component of the p53 pathway, acting as a
specific deubiquitinase for p53, Mdm2, and Mdm4 (14). The
Mdm2, Mdm4, and HAUSP proteins thus maintain p53 protein
levels and activities, which are critical for an appropriate p53
transcriptional response to occur after a stress signal or in
response to fertilization and implantation in the uterus (Fig. 4).
In humans, functional SNPs have been identified in both p53
and its negative regulator, Mdm2, which can alter the levels or
function of p53. Interestingly, it appears that these SNPs (the p53
R72 allele and the G allele in Mdm2) are under evolutionary
positive selection pressure in Caucasian and Asian populations
(10, 11). Recent studies with the haplotypes of SNPs in the
Mdm4 and Hausp genes also demonstrated the positive evolu-
tionary selection toward selected alleles in these 2 genes in
Caucasian populations. These observations suggested that p53
has evolutionarily conserved functions other than as a tumor
suppressor. p53-like transcription factors are conserved from
invertebrates to vertebrates, and the existence of p53-like pro-
teins in short-lived organisms that do not exhibit adult cancer
incidence, such as flies and worms, suggests that tumor suppres-
sion was not the original function for p53 and its pathway.
Indeed, there is some evidence for p53 in reproduction and
fecundity. In Drosophila and Caenorhabditis elegans, a p53-like
protein is most commonly expressed in germ cells, and it
functions in the surveillance of damaged DNA in germ cells to
eliminate defective offspring from the population (16). In mice,
p53 regulates blastocyst implantation through its target gene,
LIF (3). This study demonstrates the association of SNPs in the
p53 pathway with human fertility and strongly suggests that p53
regulates human fertility.
LIF is an important factor for implantation in humans. The
LIF levels are significantly higher in cells with p53R72 compared
with isogenic cells with P72, a SNP with weaker p53 transcrip-
tional activity. Therefore, altering the p53 activity by this SNP
could result in different uterine LIF levels and implantation
rates, which lead to different pregnancy outcomes in a human
population. As shown in this report, p53 P72 is significantly
enriched in IVF patients, especially in patients younger than 35
years of age. Furthermore, young patients homozygous for P72
have significantly lower implantation and pregnancy rates after
IVF compared with patients carrying at least 1 allele of R72. Our
results suggest that this p53 codon 72 polymorphism may in-
crease the risk of implantation failure to a subset of young
women under the age of 35 years undergoing IVF because of the
lower LIF levels. Providing LIF to these patients at the implan-
tation stage could potentially enhance their chance for preg-
nancy. For older patients in whom chromosomal aneuploidy and
quality of the embryo seem to bemajor reasons for infertility, the
enrichment of p53 P72 is less significant. These results strongly
support the role of p53 in regulation of implantation and fertility
in humans. Our observation is consistent with a recent report
from Coulam and colleagues (5) showing that p53 P72 is
associated with recurrent implantation failure in humans but is
inconsistent with the result from another report that failed to
observe such an association (17). However, the latter report used
a cohort of patients who had an average age of 35–37 years and
underwent fresh IVF procedure using their own oocytes. There-
fore, the effect of aneuploidy on infertility from older women
could be an important reason why the researchers failed to
observe this association. Interestingly, the frequency of the p53
P72 allele (33%) in their cohort is very close to that in the patient
cohort (33.1%) reported here, suggesting that there is potential
enrichment of the p53 P72 allele in their cohort. They missed this
observation because there was no control group included in their
study. This may explain why no association of p53 codon 72 SNP
with implantation and fertility was observed in their study,
whereas in this study, each of 5 independent SNPs in different
genes that interact epistatically within the p53 pathway all
showed an association with human fertility, but only in women
under the age of 35 years.
The Mdm2 SNP309 is a functional SNP that increases Mdm2
expression levels and attenuates the p53 pathway. SNPs inMdm4
and Hausp genes can influence the functions of the p53 pathway,
and the G allele of SNP 309 is associated with an increased
cancer risk and a lower age of onset of cancers. There is a
significant association of the Mdm2 SNP309 G allele and the A
allele of Hausp gene with infertility in young patients but not in
the older patients, which is similar to the observation made with
p53 codon 72. These results suggest that Mdm2 and Hausp may
be involved in the regulation of human fertility through p53 and
its regulation of implantation. The association of the T allele of
Mdm4with infertility is observed in both young and older patient
groups, suggesting that Mdm4 may regulate human fertility
through p53-dependent and p53-independent pathways. Mdm4
interacts and inhibits not only p53 but other p53 family members,
such as p63 and p73 (18). p63 plays an important role in DNA
damage-induced apoptosis in primordial follicles in the female
germ line (19). p73 encodes 2 major isoforms, TA p73, which
contains the conserved TA domain and is highly homologous to
the full-length of p53, andNp73, which lacks the N-terminal TA
domain. TA p73/ mice also show a phenotype of infertility in
female mice (20). Thus, it will be interesting to study the
Mdm2 p53MDMX
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Fig. 4. SNPs in p53 and the p53 pathway associated with human fertility.
Naturally occurring polymorphisms in the p53 pathway listed in the diagram,
which modify the function of the p53 pathway, could have an impact on
human fertility.
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potential role of p63 and p73 in human fertility in the future. The
association of these SNPs with human infertility strongly indi-
cates the involvement of the p53 pathway and family of tran-
scription factors in fertility (Fig. 4). The minor alleles of all SNPs
tested in this study are enriched in IVF patients, which demon-
strates that the major allele of these SNPs contributes to
improved fertility in Caucasian populations. This observation
may explain the evolutionary positive selection of alleles of some
SNPs in the p53 pathway. Obviously, these conclusions are not
valid for African and African-American populations.
In summary, these data strongly suggest that the p53 pathway
plays an important role in human fertility. Identifying higher risk
polymorphisms for pregnancy failure could provide patients with
more accurate predictions of their IVF success rates.
The functions of selected alleles in the p53 pathway genes
explored here in fertility and in cancer demonstrate a cooper-
ative pleiotropy; however, they demonstrate an antagonistic
pleiotropy when the phenotypes of fertility and life span are
compared. The functions of certain alleles being selected for in
different genetic backgrounds (in Caucasian and Asian popula-
tions but not in African populations) emphasize the need for
well-matched case-control populations. This also suggests that
some of these same alleles could participate in hybrid dysgenesis
leading to infertility as previously isolated groups begin to mate.
Materials and Methods
Cell Lines. Soas2-ts cells containing either P72 or R72 in the expression plasmid
of p53 were established as previously described (7). Cells were maintained at
39 °C in DMEM supplemented with 10% vol/vol FBS and 400 g/mL G418.
Human melanoma cell lines WM115 carrying homozygous p53 R72 and
WM278 cell lines carrying homozygous p53 P72 were derived from primary
nonmetastatic tumors and were maintained in DMEM supplemented with
10% vol/vol FBS (7).
Study Participants.
1. Lymphoblastoid cell lines from the Coriell Diversity Cell Line panel. Lym-
phoblastoid cell lines (Caucasian 100) established from healthy Caucasian
individuals (n  100) were obtained from the Coriell Diversity Cell Line
panel (Coriell).
2. The control group of theWISE study. The population of theWISE study has
been described in detail previously (21). The present study involved 1,504
Caucasian female controls from the age of 50–79 years with no history of
cancer at any site and having intact ovaries before menopause. In this
population, 91% of women have ever been pregnant, which is very similar
to the fertility frequency obtained from the U.S. National Survey of Family
Growth, 1988–1995 (22).
3. Patients from an IVF clinic. A total of 272 women with unexplained infer-
tility from the Center for Reproductive Medicine and Infertility at Weill
CornellMedical Collegewere prospectively enrolled in this study. Of these,
106patientswereolder than35yearsof ageand166patientswereyounger
than35 years of age. Patientswith severemale factor, poorovarian reserve,
or mu¨llerian anomalies were excluded from the study. Patients underwent
long (agonist) IVF protocols using luteal Lupron and gonadotropin stimu-
lation in a step-down fashion.
Implantation rate was calculated as gestations sacs/embryo transferred. Preg-
nancy ratewas defined as the detection of a serumhCG level5mIU/mL 9–11
days after embryo transfer. Clinical pregnancy rate was defined as the pres-
ence of fetal cardiac activity at 6–7 weeks of gestation.
Data collectionwas in accordwith an Institutional Review Board-approved
protocol.
Quantitative Real-Time PCR. Total RNA was prepared from cells using an
RNeasy kit (Qiagen). Real-time PCR was performed in triplicate with Taqman
PCR Mix (Applied Biosystems) in the 7000 ABI sequence Detection System
(Applied Biosystems). All primers were purchased from Applied Biosystems.
The expression of p53 target genes was normalized to -actin gene.
Genotyping. SNPs genotyped in this study include p53 codon 72 SNP
(rs1042522), Mdm2 SNP309 (rs2279744), SNP in LIF gene (rs929271), Mdm4
gene (rs1563828), and Hausp gene (rs1529916).
The status of these SNPswas determined in theWISE control groupbyusing
the ABI PRISM SNaPshot Multiplex Kit (Applied Biosystems) following the
standard protocol as previously described (21). Genotypes were determined
using GeneMapper 4.0 (Applied Biosystems).
The statusof these SNPswasdetermined in the rest of the studyparticipants
by using a Taqman SNP genotyping assay. All primers were purchased from
Applied Biosystems.
Data Collection and Statistical Methods. For the cohort of the WISE control
population, a detailed questionnaire was used to assess prior medication use
as well as exposures and reproductive history. OR estimates and 95%CIs were
calculated to evaluate the relation between LIF polymorphism and prior use
of fertility medications.
Multiple conditional logistic regression was used to account for age at the
interview. Other confounder variables were considered, including reproduc-
tive history and exposure factors, such as exogenous hormone use. A variable
was considered as a confounder if it changed the point estimate of any
genotype effect by 10% or more.
Differences in genotype/allele distribution were evaluated using 2 analysis.
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